Conference Dates: October 3 - 5, 2002
Conference Location: New York, New York, USA
Sponsoring Group: Imedex, Inc.
Conference Web Page URL: www.imedex.com/announcements/l&m02.htm
Topics Covered: Myeloma-Basic Science, Plasma Cell Dyscrasias and Other Lymphoplasmacytic Disorders, Bone Disease, Chemotherapy for Myeloma and for Lymphoma, New Treatments for Myeloma, The Biology of Lymphoma, Novel Therapies for Lymphoproliferative Disorders, Monoclonal Antibodies for the Treatment of Lymphoma, Hodgkin's Disease
Conference Objectives: After successfully completing this program, participants should be able to:
Who Should Attend: This program is designed for hematologists, medical oncologists, translational researchers, basic scientists, and other health care providers with an interest in lymphoproliferative and plasma cell disorders and their management.
Registration Information: Online: www.imedex.com, Fax: 770-751-7332, Telephone: 770-751-7334, Mail: Imedex, Inc. 70 Technology Drive, Alpharetta, GA 30005
Conference Fees: Physicians: $295 by August 30, $395 by September 20, $495 after Sept. 20 Nurses, Fellows and Residents: $149 by August 30, $249 after August 30
Continuing Education: Yes
Miscellany: Imedex, USA, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Imedex, USA, Inc. designates this continuing medical education activity for a maximum of 22 credit hours in Category 1 of the Physician's Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
Feb 20, 2012 - In the United States, the use of partial nephrectomy procedures to manage renal masses in patients with renal cell carcinoma increased significantly from 2002 to 2008, according to research published in the March issue of The Journal of Urology.
Feb 20, 2012
Sep 26, 2011
Mar 2, 2011
Apr 23, 2014